7th Annual Achieving Quality & Process Excellence in the Pharmaceutical Industry

Fleming Europe24 - 25 May 2011, Barcelona, Spain.
What are the new approaches to quality to achieve world-class manufacturing performance? How can you successfully introduce innovation and continual improvement into manufacturing?

Continuing pressures on life sciences manufacturing, from increased competition to regulatory requirements, are forcing organizations to achieve tighter operating efficiencies, while improving their ability to satisfy quality compliance standards.

Leading Pharma companies are now looking to Lean Manufacturing and Six Sigma principles to help them boost operational efficiency and improve quality. Explore the importance of six sigma in process validation and how to successfully apply Lean approach in Quality Assurance to simplify the processes.

Discuss with leading experts, how to build a sustainable quality culture during the times of change. Understand how to apply QbD tools during method development phase to achieve robust and reliable analytical procedures. Gain critical insights & first-hand experience how to incorporate risk management thinking and practices across the entire organization.

This event will bring together senior industry quality & operational excellence experts from the Pharmaceutical industry presenting real life case studies as well as a lot of networking sessions and discussions.

Key speakers:

  • Head of Quality Control, Sanofi Aventis, Germany
  • Senior Vice President Quality Assurance, Glenmark Pharmaceuticals, India
  • Head Operational Excellence & Lean, AstraZeneca, Sweden
  • Director Turbuhaler, AstraZeneca, Sweden
  • Quality Assurance Projects, Abbott, Italy
  • Head of Processes & Product Quality, Belupo, Croatia
  • More speakers to be announced

Key topics:

  • Explore Process Innovations for Operational Excellence
  • Enhance six sigma strategies to control costs, improve productivity and maintain compliance – how to integrate Quality & Operational Efficiency
  • Understand, how to link quality to performance
  • Reveal new approaches & tools for facilitating continuous improvement - building a sustainable quality culture and getting the right thinking across the entire organization
  • Maximize the benefits of QbD and Process understanding - best practices in QbD & PAT
  • Embrace Quality Risk Management - from theory to practice
  • Deployment of quality management for biologics - new challenges in aseptic processing of biologics
  • Understand new regulatory aspects of modern quality management and being prepared for the inspection

PLUS 3 Interactive Workshops:

  • Achieving efficiency in Quality Control
  • Application of Lean approach to Quality Assurance
  • Quality Risk Management - the new paradigm

Who should attend:
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Quality Management, Quality Assurance, Quality Operations, Quality Control, Quality Systems, Regulatory Affairs, GMP Compliance, Quality by Design, PAT, Lean/Six Sigma, Lean Manufacturing, API manufacturing, Technical operations, Contract Manufacturing, Operational Excellence, Business Process Excellence, Operations, Production, Manufacturing, Supply Chain, Quality Risk Management, Qualified Person, Right First Time leaders.

For further information and registration, please visit:
http://flemingeurope.com/pharmaceuticals-conferences/europe/7th-annual-achieving-quality-process-excellence-in-the-pharmaceutical-industry

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...